Exicure (NASDAQ:XCUR) Stock Price Down 5.8% - What's Next?

Shares of Exicure, Inc. (NASDAQ:XCUR - Get Free Report) were down 5.8% on Tuesday . The company traded as low as $8.32 and last traded at $8.32. Approximately 2,680 shares changed hands during trading, a decline of 100% from the average daily volume of 558,368 shares. The stock had previously closed at $8.83.

Exicure Trading Down 2.0%

The firm has a market cap of $47.21 million, a PE ratio of -1.55 and a beta of 3.71. The stock has a fifty day simple moving average of $10.16 and a two-hundred day simple moving average of $11.76.

Exicure (NASDAQ:XCUR - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC acquired a new position in shares of Exicure, Inc. (NASDAQ:XCUR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,645 shares of the company's stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure at the end of the most recent quarter. Institutional investors and hedge funds own 42.82% of the company's stock.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.